Doxorubicin-anti-CEA monoclonal antibody conjugate

Drug Profile

Doxorubicin-anti-CEA monoclonal antibody conjugate

Alternative Names: DOX-CEA; Doxorubicin anti-CEA; Doxorubicin-anti-CEA antibody conjugate; Doxorubicin-anti-CEA conjugate

Latest Information Update: 14 Nov 2000

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Immunomedics
  • Class Monoclonal antibodies
  • Mechanism of Action Reactive oxygen species stimulants; RNA synthesis inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 14 Nov 2000 Discontinued-Preclinical for Cancer in USA (Unknown route)
  • 13 Nov 2000 Preclinical study results have been added to the pharmacokinetics and Cancer pharmacodynamics sections
  • 07 Nov 1997 Preclinical development for Cancer in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top